Our group aims to explore the role of a novel family of enzymes known as ‘2-oxoglutarate oxygenases’ in cancer. These enzymes depend on 2-oxoglutarate (2OG), oxygen and Fe(II) to catalyse oxidative modifications such as hydroxylation and demethylation. 2OG-oxygenases have been linked to cancer following their known involvement in hypoxia signalling and epigenetic regulation, and their altered expression, amplification and mutation observed in cancer genetics programs.
We have shown that a sub-set of 2OG-oxygenases hydroxylate substrates involved in the control of protein synthesis, including ribosomal proteins Rpl27a and Rpl8. Interestingly, the expression of these enzymes is deregulated in multiple tumour types. Since aberrant protein synthesis and translational control are critical features of cancer development and progression, our group aims to understand how regulation of protein translation by hydroxylation may contribute to tumourigenesis.
Our research on 2OG-oxygenases in cancer involves a multi-disciplinary approach that includes in vitro biochemical assays (interaction and enzyme modification assays, crystallography), gene knockout and RNA interference in tumour cell lines, and model organisms. In order to achieve this breadth of research we collaborate with several UK and international groups including Professor’s Peter Ratcliffe, Christopher Schofield, Xin Lu, Benedikt Kessler and Adrian Harris (Oxford), Professor Anne Willis (Leicester), Associate Professor Mark Bix (Memphis), Dr Stephen Renshaw (Sheffield), Dr Marion Schmidt-Zachmann (Heidelberg) and Dr Elena Alkalaeva and Professor Ludmila Frolova (Moscow).